Filtered By:
Cancer: Squamous Cell Carcinoma
This page shows you your search results in order of relevance. This is page number 10.
Order by Relevance | Date
Total 25044 results found since Jan 2013.
Clinical efficacy of anlotinib plus S-1 as a second-line therapy for recurrent or metastatic esophageal squamous cell carcinoma
The objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS) and adverse effects were evaluated for all the patients.OBJECTIVE: No complete remission (CR) was observed in the 26 patients. Partial remission (PR) was achieved in 6 cases, stable disease (SD) in 12 cases, and progressive disease (PD) occurred in 8 cases, with an ORR of 23.1% and a DCR of 69.2% in these patients. The median PFS was 4.5 months (95%CI: 2.7-6.4 months). Univariate analysis showed that the patients with moderate or high tumor differentiation had significantly longer PFS than those with low tumor differentiation (6....
Source: Journal of Southern Medical University - February 24, 2021 Category: Universities & Medical Training Authors: W Sun X Zou W Zhang S Hu K Ge Source Type: research
